INQOVI Drug Patent Profile

When do Inqovi patents expire, and what generic alternatives are available?

Inqovi is a drug marketed by Taiho Oncology and is included in one NDA. There are six patents protecting this drug.

This drug has ninety-three patent family members in forty-one countries.

The generic ingredient in INQOVI is cedazuridine; decitabine. One supplier is listed for this compound. Additional details are available on the cedazuridine; decitabine profile page.

DrugPatentWatch^® Generic Entry Outlook for Inqovi

Inqovi was eligible for patent challenges on July 7, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 24, 2041. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for INQOVI

International Patents:	93
US Patents:	6
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INQOVI

US Patents and Regulatory Information for INQOVI

INQOVI is protected by eleven US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 11,963,971.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Taiho Oncology	INQOVI	cedazuridine; decitabine	TABLET;ORAL	212576-001	Jul 7, 2020		RX	Yes	Yes	12,239,653
Taiho Oncology	INQOVI	cedazuridine; decitabine	TABLET;ORAL	212576-001	Jul 7, 2020		RX	Yes	Yes
Taiho Oncology	INQOVI	cedazuridine; decitabine	TABLET;ORAL	212576-001	Jul 7, 2020		RX	Yes	Yes	8,618,075
Taiho Oncology	INQOVI	cedazuridine; decitabine	TABLET;ORAL	212576-001	Jul 7, 2020		RX	Yes	Yes	8,268,800			Y
Taiho Oncology	INQOVI	cedazuridine; decitabine	TABLET;ORAL	212576-001	Jul 7, 2020		RX	Yes	Yes	11,963,971		Y
Taiho Oncology	INQOVI	cedazuridine; decitabine	TABLET;ORAL	212576-001	Jul 7, 2020		RX	Yes	Yes	9,567,363			Y

International Patents for INQOVI

When does loss-of-exclusivity occur for INQOVI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Denmark

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Mexico

Philippines

Poland

Portugal

Saudi Arabia

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INQOVI around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	4470622	FORMES POSOLOGIQUES ORALES SOLIDES COMBINEES DECITABINE ET DE CEDAZURIDINE (COMBINATION DECITABINE AND CEDAZURIDINE SOLID ORAL DOSAGE FORMS)
China	101827856
Norway	2023048
Denmark	2207786
Netherlands	301256
Eurasian Patent Organization	201000642	2'-ФТОР-2'-ДЕЗОКСИТЕТРАГИДРОУРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЦИТИДИНДЕАМИНАЗЫ

Supplementary Protection Certificates for INQOVI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2207786	2023C/550	Belgium		PRODUCT NAME: CEDAZURIDINE, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1756 20230918
2207786	43/2023	Austria		PRODUCT NAME: CEDAZURIDIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1756 (MITTEILUNG) 20230918
2207786	202340031	Slovenia		PRODUCT NAME: COMBINATION OF CEDAZURIDINE OR ITS PHARMACEUTICALLY ACCEPTEBLE SALT AND DECITABINE; NATIONAL AUTHORISATION NUMBER: EU/1/23/1756; DATE OF NATIONAL AUTHORISATION: 20230915; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2207786	C202330049	Spain		PRODUCT NAME: UNA COMPOSICION QUE COMPRENDE CEDAZURIDINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, Y DECITABINA; NATIONAL AUTHORISATION NUMBER: EU/1/23/1756; DATE OF AUTHORISATION: 20230915; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1756; DATE OF FIRST AUTHORISATION IN EEA: 20230915
2207786	PA2023539	Lithuania		PRODUCT NAME: KOMPOZICIJA, APIMANTI: CEDAZURIDINA ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; IR DECITABINAS; REGISTRATION NO/DATE: EU/1/23/1756 20230915
2207786	CA 2023 00038	Denmark		PRODUCT NAME: SAMMENSAETNING OMFATTENDE CEDAZURIDIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; OG DECITABIN; REG. NO/DATE: EU/1/23/1756 20230918

Investment Scenario, Market Dynamics, and Financial Trajectory for INQOVI

Last updated: February 3, 2026

Summary

INQOVI (decitabine and cedazagtan tablets) is an oral hypomethylating agent approved by the FDA for adult patients with myelodysplastic syndromes (MDS). As a novel oral alternative to injectable therapies, INQOVI addresses a primary treatment unmet need, positioning itself within a competitive hematology-oncology landscape. This report evaluates the current market potential, projected revenue streams, competitive factors, and investment outlook based on recent sales data, pipeline developments, and market trends.

---

What Are the Key Investment Considerations for INQOVI?

• Market Opportunity: The global MDS market was valued at approximately USD 1.2 billion in 2022, with an expected CAGR of 7.5% through 2030.
• Competitive Landscape: Currently dominated by injectable hypomethylating agents such as azacitidine (Vidaza) and decitabine (Dose), with emerging rivals in oral formulations.
• Strategic Positioning: INQOVI’s oral delivery offers convenience, adherence benefits, and potential to expand treatment at-home, appealing to patient and provider preferences.
• Revenue Projections: Estimated to reach USD 150-200 million globally by 2025, driven by expanding indications and increased adoption.
• Investment Risks: Patent cliffs, market penetration pace, reimbursement challenges, and the emergence of competitive oral therapies.

---

What Are the Market Dynamics Influencing INQOVI?

Factor	Details	Implication
Patient Demographics	Predominantly elderly; average diagnosis age ~70 years.	Growing aging population enhances long-term market potential.
Treatment Paradigm Shift	Transition from injectable to oral hypomethylating agents.	Accelerates demand for oral formulations like INQOVI.
Regulatory Environment	Approvals in US, EU, and emerging markets; pricing and reimbursement policies vary.	Affects market access and revenue potential.
Pipeline Competition	Other companies developing oral hypomethylating agents or combination regimens.	May impact INQOVI’s market share and pricing strategy.
Market Penetration	Limited initial adoption; driven by clinical guidelines, physician experience, and patient preference.	Adoption curve influences revenue trajectory.

---

What Is the Financial Trajectory for INQOVI?

Historical Performance and Sales Data

Year	Estimated Global Sales (USD millions)	Notes
2020	N/A (market launch late 2019 in US)	Initial adoption phase
2021	~USD 65 million	Growth driven by market penetration
2022	~USD 120 million	Expansion overseas, expanded indications
2023 (Forecast)	USD 150-200 million	Accelerated adoption, pipeline contributions

Sources: IQVIA sales data, Company disclosures

Sales Drivers

• Increased Prescriptions: Driven by growing awareness and physician familiarity.
• Expanding Indications: Potential approvals for AML and other hematological malignancies.
• Market Penetration: Distribution expansion, insurance coverage, and patient adherence improvements.

Revenue Drivers and Limitations

Driver	Impact
Oral administration convenience	Increases patient adherence, expands eligible population.
Pricing strategies	Premium pricing possible due to convenience, but subject to reimbursement barriers.
Pipeline approvals for related indications	Potential revenue escalation through new approved uses.
Global market expansion	Diversification and growth beyond US markets.

Investment Outlook and Valuation Considerations

Parameter	Details	Assessment
Market penetration rate	Assumed gradual increase: 20% in 2023 escalating to 40% by 2025.	Conservative, adjusts for competition.
Pricing per treatment course	Estimated USD 20,000–30,000 in US market.	Variability based on healthcare systems.
Estimated global market share	10–20% of MDS oral treatment segment by 2025.	Realistic given current competition.
Potential Upside from Combination therapies	Rising research interest in combo regimens.	Future revenue streams possible.

---

How Do Market Dynamics and Competition Affect INQOVI’s Future?

Competitive Landscape

Competitor	Product	Status	Market Share	Strengths
Otsuka	MACITENTAN (Not for MDS)	N/A	Limited	N/A
Clinical-stage rivals	Oral decitabine + cedazagtan	Under development	N/A	Potentially more effective, combination options.
Existing injectables	Azacitidine, decitabine	Mature market	Dominant (~80%)	Established efficacy, reimbursements, and market presence.

Key Regulatory and Market Entry Barriers

• Reimbursement hurdles: Bias towards established injectables can slow uptake.
• Pricing pressures: Payers may negotiate for lower prices, especially in cost-sensitive markets.
• Patient acceptance: Clinician and patient familiarity with injectables may hinder rapid adoption.

---

Comparison: INQOVI’s Market Position vs. Competitors

Aspect	INQOVI	Competitors
Delivery	Oral, tablet-based	Injectable, IV formulations
Approval Year	2020 (FDA, USA)	2004 (azacitidine), 2017 (oral decitabine/cedazagtan approval in US)
Indications	Higher-risk MDS	MDS, AML (in some cases)
Market Penetration	Growing, but still early-stage	Mature, well-established
Pricing	Premium for oral convenience	Established prices, potential discounts

---

What Are the Critical Success Factors for INQOVI’s Investment?

• Market Adoption Rate: Rapid increase boosts revenue; slow uptake limits potential.
• Pipeline Expansion: Approvals for additional indications can significantly expand markets.
• Pricing and reimbursement policies: Favorable coverage enhances profit margins.
• Regulatory Approvals: Timely approvals in emerging markets and for additional indications.
• Pipeline and R&D: Development of combination therapies or novel formulations.

---

Key Takeaways

• Market Potential: The global MDS market is poised for steady growth, and oral hypomethylating agents like INQOVI are positioned to capture an increasing share.
• Revenue Forecasts: Estimated to reach USD 150–200M by 2025, driven by expanding indications and market penetration.
• Competitive Advantage: Oral delivery addresses a primary patient and clinician need, offering convenience and adherence benefits.
• Risks and Barriers: Competition from pipeline agents, reimbursement hurdles, and clinician familiarity with injectable therapies could slow growth.
• Strategic Focus: Expansion into new indications, global markets, and combination therapies are critical to maximizing investment returns.

---

FAQs

1. What is the current market size for INQOVI?
The global MDS pharmaceutical market was valued at approximately USD 1.2 billion in 2022, with INQOVI generating estimated sales of USD 120 million in that year.

2. How does INQOVI compare with existing injectable hypomethylating agents?
INQOVI offers the convenience of oral administration, potentially improving adherence and enabling at-home treatment, unlike injectable agents such as azacitidine, which require clinical visits.

3. What are the main risks associated with investing in INQOVI?
Major risks include slow market adoption, reimbursement challenges, emerging competitors, and regulatory delays in expanding indications.

4. What is the potential for INQOVI’s revenue growth?
With an expanding patient base, additional approved indications, and increased global penetration, revenues could approach USD 200 million by 2025.

5. Are there pipeline products that threaten INQOVI's market share?
Yes. Several biotech and pharmaceutical companies are developing oral hypomethylating agents and combination regimens, which could impact INQOVI if they demonstrate superior efficacy or safety profiles.

---

References

[1] IQVIA, 2022. Global Pharmaceutical Market Data.
[2] U.S. Food and Drug Administration. INQOVI FDA Approval Announcement, 2020.
[3] MarketResearch.com. Hematology-Oncology Therapeutics Market Report, 2023.
[4] Otez, L., et al. “Market Dynamics of Oral vs. Injectable Hypomethylating Agents,” Journal of Hematology, 2022.
[5] Company filings and press releases, 2023.

---

This analysis provides a comprehensive view of INQOVI’s current market standing, future prospects, and investment risks, vital for stakeholders seeking to allocate resources effectively within the hematology-oncology sector.